SGMO Profile
Sangamo Therapeutics, Inc., a pioneering clinical-stage biotechnology firm, specializes in harnessing platform technologies such as gene therapy, cell therapy, genome editing, and genome regulation to develop transformative genomic medicines. The company's core technology is the zinc finger protein (ZFP) platform, which enables the creation of zinc finger nucleases for modifying DNA sequences and ZFP transcription factors for regulating gene expression.
At the forefront of innovation, Sangamo Therapeutics is advancing a robust pipeline of therapies aimed at addressing significant medical needs. This includes SB-525, currently undergoing Phase III AFFINE clinical trials for hemophilia A treatment, and ST-920, a gene therapy in Phase I/II STAAR trials for Fabry disease. Additionally, SAR445136, a cell therapy, is progressing through Phase I/II PRECIZN-1 trials targeting sickle cell disease.
The company also focuses on developing cutting-edge treatments like TX200 for HLA-A2 mismatched kidney transplant rejection, KITE-037 for cancer cell therapy, ST-501 for tauopathies, and ST-502 for synucleinopathies including Parkinson's disease and neuromuscular disorders. Sangamo Therapeutics collaborates extensively with industry leaders and strategic partners such as Biogen MA, Inc., Kite Pharma, Inc., Pfizer Inc., Sanofi S.A., and Novartis Institutes for BioMedical Research, Inc., among others.
Founded in 1995 and headquartered in Brisbane, California, Sangamo Therapeutics was formerly known as Sangamo BioSciences, Inc. The company rebranded to Sangamo Therapeutics, Inc. in January 2017 to better reflect its commitment to advancing therapeutic solutions through innovative genomic approaches. With a robust portfolio and strong collaborative network, Sangamo Therapeutics continues to drive advancements in genomic medicine, aiming to improve patient outcomes worldwide.
|
